Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease

Documenti analoghi

• Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH
  di: Jannis Kountouras, et al.
  Pubblicazione: (2024)
• Letter: H. pylori Infection May Constitute a Risk Factor for Reflux Disease and Colonic Neoplasia
  di: Jannis Kountouras, et al.
  Pubblicazione: (2025)
• Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
  di: Jannis Kountouras, et al.
  Pubblicazione: (2024)
• Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
  di: Stergios A. Polyzos, et al.
  Pubblicazione: (2024)
• A Potential Impact of Helicobacter pylori Infection on Gastroesophageal Reflux Disease
  di: Jannis Kountouras, et al.
  Pubblicazione: (2026)